RAvVA trial

Chief investigator - Professor Charles Craddock, University Hospital Birmingham
A randomised phase II trial of 5-azacitidine versus 5-azacitidine in combination with vorinostat in patients with relapsed acute myeloid leukaemia ineligible for salvage chemotherapy
Amount awarded: 5.5 years (68 months)
Award start date: 01 Aug 2011
Recruitment start date: 25 Sep 2012
Award duration: 5.5 years (68 months)

In this trial, researchers are looking at two drugs called azacitidine and vorinostat.

Azacitidine is a type of chemotherapy drug that doctors already use to treat people with AML and MDS. Its exact mechanism of action is unknown, and it has more than one effect on cells. In AML and MDS, important genes that regulate cell growth and division are turned off by methyl groups becoming attached to the cells’ DNA, allowing cells to grow out of control. Azacitidine can act as a demethylating agent, removing the methyl groups and restoring normal gene function.

Vorinostat inhibits proteins (enzymes) called histone deacetylases - cells need these enzymes to grow and divide. Drugs that block these enzymes are called histone deacetylase inhibitors, or HDAC inhibitors.

The aim of the trial is to:

  • See if combining azacitidine and vorinostat is better than azacitidine alone

This trial is closed for recruitment, and we hope to update you with the results soon.